© Drug Hunter Inc. 2018-2023
Home > “compound 25”
mutant KRASG12C allosteric covalent inhibitor
orally efficacious in XG model
from optimization of literature starting point
J. Med. Chem. Feb. 5, 2020
AstraZeneca, Cambridge, UK
KRAS(G12C) inhibitor from AZ (AstraZeneca oral in vivo mutant KRAS(G12C) allosteric covalent inhibitor)
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year